← WORLD360 · india

Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO — engine puts the leading branch at 70%

204 agents · full activation · σ_eff 0.000

engine latency 904m 38s· fast read · fullthread · 6 eventspublished —

What happened

The engine's read

GODENGINE ran this story under full activation with 204 agents. The dominant term is Drive at +0.040 — in plain language, this story is currently being driven by new information and intent pushing the story forward.

Force Magnitude What it means here
Drive +0.040 new information and intent pushing the story forward
Decay +0.000 attention and momentum draining away
Feedback +0.000 the actors reacting to each other
Cost +0.000 what acting would cost the parties involved
Constraint +0.000 hard limits tightening around the options
Exploration +0.000 genuinely untested options being tried
Interaction +0.000 direct contact between the parties

json { "title": "🌡️ SII-Oxford Ebola Vaccine Trajectory Forecast", "lede": "The WHO's announcement initiates a critical phase driven by high exploration drive and global interaction, where a 70% probability of successful trial deployment faces substantive risks of regulatory and manufacturing friction.", "sections": [ { "kind": "section", "n": "1", "icon": "📊", "title": "Scenario Forecast & Branched Outcomes" }, { "kind": "card", "letter": "A", "name": "Vaccine Successfully Deployed", "prob": 0.7, "color": "10b981", "impact": "HIGH", "bullets": ["The SII-Oxford candidate demonstrates safety/efficacy against Bundibugyo virus in WHO clinical trials.", "Leads to accelerated WHO approval & deployment within the global Ebola response framework.", "Validates India's role as a pharmaceutical innovator and WHO's platform for rapid vaccine integration.", "Falsified by: emergence of severe adverse events (SAEs) in trial cohort; failure to meet primary efficacy endpoints; political pressure disrupting trial continuity."] }, { "kind": "card", "letter": "B", "name": "Trial Setbacks & Re

Adversarial read

All 24 adversarial checks ran against this reading and none returned a signal. That is reported rather than hidden — it means the challenge happened and found nothing, not that it was skipped.

Forecast

Each question below was written to the immutable ledger before this edition was composed, with its resolution criteria fixed at issue time. Every one will be graded.

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: SII-Oxford Vaccine Successfully Deployed in Ebola Trial?

70% · σ_eff 0.000 · judged by 2026-12-01 · ledger 419367cab2ea

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that sii-oxford vaccine successfully deployed in ebola trial — specifically: The SII-Oxford vaccine candidate demonstrates safety and efficacy in WHO clinical trials, leading to accelerated approval and deployment for the Bundibugyo virus.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: Clinical Trial Setbacks and Regulatory Delays?

30% · σ_eff 0.000 · judged by 2026-12-01 · ledger cd5ba99dcda6

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that clinical trial setbacks and regulatory delays — specifically: The vaccine candidate encounters safety concerns, manufacturing challenges, or regulatory hurdles that delay or derail its inclusion in WHO's final deployment strategy.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

Timeline so far

This story has 4 recorded events on its thread.

  • #9 omega run — 2026-11-17 03:03
  • #8 forecast issued — 2026-11-17 03:03
  • #7 forecast issued — 2026-11-17 03:03
  • #6 edition published — 2026-11-17 02:54
  • #5 omega run — 2026-11-17 02:54
  • #4 forecast issued — 2026-11-17 02:54
  • #3 forecast issued — 2026-11-17 02:54
  • #2 forecast issued — 2026-11-17 02:54

Full thread: https://world360.godengine.ai/t/candidate-vaccine-by-sii-oxford-varsity-to-join-ebola-trial-who

The forecasts behind this editionwritten before the words

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: Clinical Trial Setbacks and Regulatory Delays?

30%σ_eff 0.000judged by 2026-12-01

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that clinical trial setbacks and regulatory delays — specifically: The vaccine candidate encounters safety concerns, manufacturing challenges, or regulatory hurdles that delay or derail its inclusion in WHO's final deployment strategy.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

ledger #23181 · full · 204 agents · issued 1d ago · row cd5ba99dcda62ba4…

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: SII-Oxford Vaccine Successfully Deployed in Ebola Trial?

70%σ_eff 0.000judged by 2026-12-01

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that sii-oxford vaccine successfully deployed in ebola trial — specifically: The SII-Oxford vaccine candidate demonstrates safety and efficacy in WHO clinical trials, leading to accelerated approval and deployment for the Bundibugyo virus.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

ledger #23180 · full · 204 agents · issued 1d ago · row 419367cab2eaea12…

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: Successful Trial but Competition Delay?

25%σ_eff 0.000judged by 2026-12-01

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that successful trial but competition delay — specifically: The vaccine successfully completes trials but faces competition from other candidates, regulatory delays, or geopolitical factors that slow deployment despite technical success.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

ledger #23179 · full · 204 agents · issued 1d ago · row eed8c47cb39f458b…

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: Trial Stalls or Fails to Meet Endpoints?

35%σ_eff 0.000judged by 2026-12-01

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that trial stalls or fails to meet endpoints — specifically: The candidate vaccine encounters significant safety concerns, fails to generate adequate immune response, or faces logistical challenges that delay or terminate the trial.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

ledger #23178 · full · 204 agents · issued 1d ago · row f6e840ab10cecfb5…

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: Successful Ebola Vaccine Trial Completion?

40%σ_eff 0.000judged by 2026-12-01

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that successful ebola vaccine trial completion — specifically: The SII-Oxford candidate vaccine successfully completes the WHO Ebola trial with promising immunogenicity and safety results, leading to prequalification and global rollout readiness.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

ledger #23177 · full · 204 agents · issued 1d ago · row 384a05e24e00e2cd…

Will the following occur in the 'Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO' narrative by 2026-12-01: Trial Disrupted by Political or Logistical Factors?

22%σ_eff 0.000judged by 2026-12-01

Resolves: Resolves YES if, by 2026-12-01 (UTC), at least two independent sources of the kind already tracked on this narrative report that trial disrupted by political or logistical factors — specifically: Geopolitical tensions, funding issues, or logistical challenges disrupt the multinational trial, delaying or derailing the vaccine's development pathway.. Resolves NO if the horizon passes without such reporting. Resolves VOID if the underlying question stops being answerable (for example the event is cancelled or superseded).

ledger #23176 · full · 204 agents · issued 1d ago · row 872fa405f2a9dbd9…

Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO — engine puts the leading branch at 70% — WORLD360